Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial

Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAFV600 mutations, targeted agents have been ineffective for BRAFV600wild-type (wt) metastatic melanomas. The SU2C Genomics-Enabled Medicine for Melanoma Trial utilized a Sim...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 16; no. 4; p. e0248097
Main Authors: LoRusso, Patricia M, Sekulic, Aleksandar, Sosman, Jeffrey A, Liang, Winnie S, Carpten, John, Craig, David W, Solit, David B, Bryce, Alan H, Kiefer, Jeffrey A, Aldrich, Jessica, Nasser, Sara, Halperin, Rebecca, Byron, Sara A, Pilat, Mary Jo, Boerner, Scott A, Durecki, Diane, Hendricks, William P D, Enriquez, Daniel, Izatt, Tyler, Keats, Jonathan, Legendre, Christophe, Markovic, Svetomir N, Weise, Amy, Naveed, Fatima, Schmidt, Jessica, Basu, Gargi D, Sekar, Shobana, Adkins, Jonathan, Tassone, Erica, Sivaprakasam, Karthigayini, Zismann, Victoria, Calvert, Valerie S, Petricoin, Emanuel F, Fecher, Leslie Anne, Lao, Christopher, Eder, J Paul, Vogelzang, Nicholas J, Perlmutter, Jane, Gorman, Mark, Manica, Barbara, Fox, Lisa, Schork, Nicholas, Zelterman, Daniel, DeVeaux, Michelle, Joseph, Richard W, Cowey, C Lance, Trent, Jeffrey M
Format: Journal Article
Language:English
Published: United States Public Library of Science 07-04-2021
Public Library of Science (PLoS)
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first